Cabotegravir Injection [Apretude]

DRUG4 trials

Sponsors

Kelley-Ross & Associates, Inc., Beth Israel Deaconess Medical Center, University of Witwatersrand, South Africa, Midway Specialty Care Center

Conditions

Breast FeedingHIV InfectionsHivPre-Exposure Prophylaxis (PrEP)

Phase 3

Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa

Active, not recruitingNCT06138600

University of Witwatersrand, South AfricaHIV Infections

Start: 2023-11-01End: 2026-01-31Target: 200Updated: 2024-06-21

Phase 4

Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana

Active, not recruitingNCT05986084

Beth Israel Deaconess Medical CenterBreast Feeding, Pre-Exposure Prophylaxis (PrEP)

Start: 2023-11-30End: 2027-08-31Target: 500Updated: 2026-07-30

Unknown Phase

Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.

CompletedNCT05867212

Kelley-Ross & Associates, Inc.HIV Infections

Start: 2023-05-13End: 2025-04-30Updated: 2025-07-29

Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP

Active, not recruitingNCT06145854

Midway Specialty Care CenterHiv

Start: 2024-01-02End: 2027-03-31Target: 100Updated: 2025-11-03